PR Newswire Clinical TrialsOriginal article
Everads Announces Publication of First-in-Human Clinical Data for Its Suprachoroidal Injector in Ophthalmology Science and Three Presentations at ARVO 2026
Data ReadoutpositiveSuprachoroidal InjectorPositive
AI Analysis
Summary
Everads Therapy announced publication of first-in-human clinical data for its suprachoroidal injector, demonstrating favorable safety, tolerability, and device performance. The company will present three additional presentations at ARVO 2026 conference.
Clinical Trial Data
Phase
Phase_1
Primary Endpoint
Met
Outcome Details
First-in-human clinical data published showing favorable safety, tolerability, and device performance with posteriorly directed drug distribution
Importance:6/10
Sentiment:
0.75
ophthalmologydeviceclinical-stagefirst-in-humanARVO 2026publication
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on May 3, 2026 1:09 PM